BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36563660)

  • 1. Relatlimab and nivolumab in the treatment of melanoma.
    Au L; Larkin J; Turajlic S
    Cell; 2022 Dec; 185(26):4866-4869. PubMed ID: 36563660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
    N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
    Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
    Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma.
    Koseła-Paterczyk H; Rutkowski P
    Expert Opin Biol Ther; 2023 May; 23(5):383-388. PubMed ID: 37200112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab and relatlimab for the treatment of melanoma.
    Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
    Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab Plus Relatlimab Is Safe and Efficacious in Pretreated Melanoma.
    Cancer Discov; 2023 Apr; 13(4):810. PubMed ID: 36825934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
    Phillips AL; Reeves DJ
    Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
    Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
    Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab Plus Relatlimab: First Approval.
    Paik J
    Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.
    Su D; Kluger H; Olino K
    Ann Surg Oncol; 2024 Mar; 31(3):1865-1879. PubMed ID: 37989956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Agent PD-1 Blockade Is "Treatment of Choice" for Desmoplastic Melanoma.
    Cancer Discov; 2023 Jun; 13(6):OF7. PubMed ID: 37071762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY.
    Raschi E; Comito F; Massari F; Gelsomino F
    Immunotherapy; 2023 Feb; 15(2):85-91. PubMed ID: 36628573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
    Lepir T; Zaghouani M; Roche SP; Li YY; Suarez M; Irias MJ; Savaraj N
    Medicine (Baltimore); 2019 Jan; 98(2):e13804. PubMed ID: 30633154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
    Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA
    J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
    Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
    Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
    Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
    Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
    Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.